Evidence map›Paper›PMID 31282311›Full record

ArticleThe neuroradiology journal2019

Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report.

Chu-Yu Lee, Amandeep Kalra, Maria V Spampinato, Ali Tabesh, Jens H Jensen, Joseph A Helpern, Maria de Fatima Falangola, Mark H Van Horn, Pierre Giglio

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The neuroradiology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chu-Yu Lee1 Department of Radiology and Radiological Science, Medical University of South Carolina, USA.ORCID https://orcid.org/0000-0001-5288-3309
Amandeep Kalra3 Department of Neuroscience, Medical University of South Carolina, USA.
Maria V Spampinato1 Department of Radiology and Radiological Science, Medical University of South Carolina, USA.
Ali Tabesh1 Department of Radiology and Radiological Science, Medical University of South Carolina, USA.
Jens H Jensen1 Department of Radiology and Radiological Science, Medical University of South Carolina, USA.
Joseph A Helpern1 Department of Radiology and Radiological Science, Medical University of South Carolina, USA.
Maria de Fatima Falangola1 Department of Radiology and Radiological Science, Medical University of South Carolina, USA.
Mark H Van Horn1 Department of Radiology and Radiological Science, Medical University of South Carolina, USA.
Pierre Giglio3 Department of Neuroscience, Medical University of South Carolina, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this preliminary study is to apply diffusional kurtosis imaging to assess the early response of recurrent glioblastoma to bevacizumab treatment.

methodsThis prospective cohort study included 10 patients who had been diagnosed with recurrent glioblastoma and scheduled to receive bevacizumab treatment. Diffusional kurtosis images were obtained from all the patients 0-7 days before (pre-bevacizumab) and 28 days after (post-bevacizumab) initiating bevacizumab treatment. The mean, 10th, and 90th percentile values were derived from the histogram of diffusional kurtosis imaging metrics in enhancing and non-enhancing lesions, selected on post-contrast T1-weighted and fluid-attenuated inversion recovery images. Correlations of imaging measures with progression-free survival and overall survival were evaluated using Spearman's rank correlation coefficient. The significance level was set at

resultsHigher pre-bevacizumab non-enhancing lesion volume was correlated with poor overall survival (

conclusionsThis preliminary study demonstrates that diffusional kurtosis imaging metrics allow the detection of tissue changes 28 days after initiating bevacizumab treatment and that they may provide information about tumor progression.

Indexed as

AdultAgedAntineoplastic Agents, ImmunologicalBevacizumabBrain NeoplasmsDiffusion Magnetic Resonance ImagingFemaleGlioblastomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalPostoperative CareProspective StudiesTreatment OutcomeAntineoplastic Agents, ImmunologicalBevacizumabbevacizumabdiffusiondiffusional kurtosis imagingdiffusion tensor imagingglioblastomaGliomas

Identifiers

PMID31282311
PMCPMC6728698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.